“…Metabolic dysfunction and use of psychotropic medication are more common among those with ASD, compared with populations with other disorders (Cheng, Rho, & Masino, 2017), and such metabolic dysfunction and psychotropic medication use may further contribute to short- and long-term central obesity and cardiometabolic risks (Barnhill, Tami, Schutte, Hewitson, & Olive, 2016). For example, lipid profiles appear to be more heterogenic in populations with ASD compared with the general population (Dziobek, Gold, Wolf, & Convit, 2007; Rossignol & Frye, 2012; Kim, Neggers, Shin, Kim, & Kim, 2010).…”